Davis Polk advised the representatives of the underwriters in connection with the $230 million initial public offering of 12,105,263 shares of common stock of Generation Bio Co., which includes 1,578,947 shares from the full exercise of the underwriters’ over-allotment option to purchase additional shares. Generation Bio Co. is listed on the Nasdaq Global Select Market under the symbol “GBIO.”

Based in Cambridge, Massachusetts, Generation Bio is an innovative genetic medicines company creating a new class of gene therapy utilizing its proprietary non-viral gene therapy platform to provide durable, redosable treatments for patients living with rare and prevalent diseases. The company is developing novel gene therapies to provide targeted delivery of genetic payloads that include large and multiple genes across a broad array of tissues and to be redosable for individualized and extended treatment throughout a patient’s life. The platform is designed to expand access to treatments for rare diseases and to address prevalent diseases through efficient, scalable manufacturing.

The Davis Polk capital markets team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associate Meaghan Kennedy. Partner David R. Bauer and associates Tilak Koilvaram, Chelsea Renter and Shuang Ci provided intellectual property advice. The tax team included partner Patrick E. Sigmon and associate Ben Levenback. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post